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Abstract (200 words)
Human D-amino acid oxidase (DAO) is a flavoenzyme that is implicated in neurodegenerative 
diseases. We investigated the impact of replacement of proline with leucine at position 219 
(P219L) in the active site lid of human DAO on the structural and enzymatic properties, because 
porcine DAO contains leucine at the corresponding position. The turnover numbers (kcat) of 
P219L were unchanged, but its Km values decreased compared to wild-type, leading to an increase 
in the catalytic efficiency (kcat/Km). Moreover, benzoate inhibits P219L with lower Ki value (0.7-
0.9 µM) compared to wild-type (1.2-2.0 µM). Crystal structure of P219L in complex with flavin 
adenine dinucleotide (FAD) and benzoate at 2.25 Å resolution displayed conformational changes 
of the active site and lid. The distances between the H-bond-forming atoms of arginine 283 and 
benzoate and the relative position between the aromatic rings of tyrosine 224 and benzoate were 
changed in the P219L complex. Taken together, the P219L substitution leads to an increase in the 
catalytic efficiency and binding affinity for substrates/inhibitors due to these structural changes. 
Furthermore, an acetic acid was located near the adenine ring of FAD in the P219L complex. The 
present study provides new insights into the structure-function relationship of human DAO. 
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D-amino acid oxidase (DAO, EC 1.4.3.3) is a flavoenzyme that catalyzes the dehydrogenation of 
D-amino acids to corresponding imino acids with concomitant reduction of flavin adenine 
dinucleotide (FAD) to reduced form (FADH2). At the active site of DAO, FADH2 is subsequently 
reoxidized by oxygen to generate hydrogen peroxide (H2O2), and the imino acid is spontaneously 
hydrolyzed to its respective 𝛼-keto acid and ammonia (Fig. S1) (1). In mammals, DAO is 
predominantly present in the kidney (2), liver (3) and brain (4, 5). We revealed the cDNA 
sequences encoding DAOs found in the kidneys of pigs (6) and humans (7), and discovered a 
single mRNA species of DAO in the porcine brain (3). In addition, the expression of the DAO 
gene is detected in type-1 astrocytes of the rat cerebellum and cerebral cortex (8). The DAO 
expressed in astrocytes is involved in the metabolism of extracellular D-serine (9). Recently, we 
detected the DAO activity and expression in the epididymis of mice, with the highest level in the 
caput region (10). 
Among D-amino acids, D-serine (D-Ser), D-alanine (D-Ala), D-proline (D-Pro), and D-leucine 
(D-Leu) are present in the brain (11). D-Ser has been proposed to serve as the physiological 
substrate for human DAO (9), and to play a role as a neurotransmitter of the N-methyl-D-aspartate 
receptor (NMDAR) (12). Therefore, dysfunction of NMDAR may be related to the alteration of 
the D-Ser level, which is regulated by DAO activity. G72 protein is an important factor to regulate 
the DAO function (13). Hypofunction of NMDAR may play a key role in the pathophysiology of 
schizophrenia (14). In contrast, hyperfunction of NMDAR can lead to excitotoxicity, which is 
implicated in neurodegenerative disorders, including Alzheimer’s disease (15) and amyotrophic 
lateral sclerosis (ALS) (16). It has been reported that the substitutions in DAO, including R199W 
and W209R are involved in ALS, while those including D31H and R279A are involved in 
schizophrenia (17-19).
In 2006, we firstly reported the three-dimensional structure of wild-type human DAO in 
complex with FAD and the competitive inhibitor benzoate at the resolution of 2.5 Å (PDB ID: 
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reported. More than a half of these structures are human DAO. Based on our previous study, 
human DAO is a homodimer, in which two monomers interact with each other in a head-to-head 
mode. Each human DAO monomer (347 amino acids, 39 kDa) contains a non-covalently bound 
FAD cofactor. Moreover, both holo and apo forms of human DAO are stable as homodimers (21). 
A distinctive feature of human DAO is its lower affinity for FAD in comparison to porcine DAO 
(20). The active sites of human and porcine DAOs are covered by a loop composed of residues 
216-228, termed the active site lid. It has been proposed that the flexibility of this loop influences 
the substrate binding and product release in DAO, because the lid is presumed to function as a 
gate for the entrance and exit of substrates (22).
The structure-function relationship of human DAO shed light on the crucial regulatory 
mechanism of D-Ser metabolism in the human brain, leading to the development of potential 
modulators of DAO for clinical applications. In line with this, the effects of amino acid 
substitutions have been assessed to elucidate the mechanism of the DAO catalysis. In comparison 
to the wild-type, the reduction rates of the Y224F and Y228F mutants of porcine DAO were 
decreased (23). The ability of the Y224F and Y224A mutants of human DAO to bind benzoate 
was also decreased (24). The access of solvent into the active site of DAO through the active site 
lid is facilitated by introducing Y55A substitution, which may affect the substrate specificity of 
the enzyme (25). Moreover, the substitution of R216-G220 of human D-aspartate oxidase for the 
active site lid of porcine DAO (I215-N225) has influenced the substrate specificity of DAO (26).
Although the genes encoding mammalian DAOs have been cloned, only DAOs from pig and 
human have been efficiently expressed in the heterologous system such as E. coli and well 
characterized. The kinetic parameters (Km, kcat, and Ki for benzoate) of human DAO (20, 21) 
seem to be similar to porcine DAO (26, 27). The Kd values of the binding between DAO and 
FAD, which were estimated by analyzing the quenching of protein fluorescence, were reported 
to be different between human and porcine DAOs (human DAO; 8 µM, porcine DAO; 0.2 µM) 
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the FAD-dependent activity of human DAO, was 0.2 µM (28). Even though the characteristics 
of human DAO have been well described previously, the functional role of Pro at the position 
219, which is conserved in most mammalian DAOs except the porcine DAO, has not been 
investigated. Therefore, Pro219 to Leu substitution (P219L) was introduced to human DAO, 
because porcine DAO has Leu at the corresponding position (29). In the present study, the 
kinetic parameters and crystal structure of P219L human DAO were analyzed and compared to 













D-Pro, D-Ala, D-Ser, FAD, potassium bromide (KBr), potassium chloride (KCl), sodium dodecyl 
sulfate (SDS), phenylmethylsulfonyl fluoride (PMSF), ampicillin, glycerol, isopropyl ß-D-1-
thiogalactopyranoside (IPTG), polyethylene glycol (PEG) 4000, ammonium acetate, and sodium 
citrate were purchased from Wako Pure Chemical Industries (Osaka, Japan). Yeast extract, 
tryptone, sodium chloride (NaCl), glucose and ammonium sulfate were obtained from Nacalai 
Tesque (Kyoto, Japan). Lysozyme and sodium benzoate were purchased from Sigma-Aldrich (St 
Louis, MO, USA). 
Bacterial cultivation and enzyme production 
E. coli cells BL21 (DE3) harboring pET11b/wild-type human DAO and pET11b/P219L human 
DAO plasmids, which were established in previous reports (20, 29) were streaked on a Luria-
Bertani (LB) agar plate (1% tryptone, 0.5% yeast extract, and 1% NaCl, w/v) containing 50 µg. 
mL-1 ampicillin and incubated at 37°C for 16 h. A single colony was inoculated into 5 mL LB 
broth media containing 50 µg. mL-1 ampicillin and incubated at 37°C for 16 h with shaking at 125 
rpm. One milliliter of starter culture (1% (v/v)) was inoculated into 100 mL of LB media in a 500 
mL flask containing 50 µg. mL-1 ampicillin and incubated at 37°C for 16 h with shaking at 125 
rpm. Twenty milliliters of starter culture (2% (v/v)) was inoculated into 1 L of fresh Terrific broth 
(1.2% (w/v) tryptone, 2.4% (w/v) yeast extract and 0.4% (v/v) glycerol in potassium phosphate 
buffer) containing 50 µg. mL-1 ampicillin, 0.5% (w/v) glucose and 250 µL of antifoam B in a 2 L 
flask. Incubation at 37°C with 170 rpm rotary shaking was performed until the OD600 reached 1.8-
2.0. The expression of DAO was induced by adding 0.1 mM IPTG. The cell culture was further 
incubated at the same condition for an additional 20 h, and then harvested by centrifugation 
(Beckman Coulter, J6-MI, Ireland) at 4,500 ×g for 45 min at 4°C. The cell pellets were 
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1 mM benzoate, 100 µM FAD, 0.5 mM dithiothreitol and 4.5 µg. mL-1 PMSF) and stored at –
80°C.
Purification of holo human DAO and the measurement of enzymatic activity
The wild-type and P219L human DAOs in holo form were purified using the modified procedure 
for recombinant DAO from pig (30) and human (20). All procedures were conducted at 4°C unless 
otherwise stated. The frozen cells were thawed and suspended in the lysis buffer. After adding 
0.5 mg. mL-1 lysozyme to disrupt E. coli cells, 1% (w/v) streptomycin sulfate was then added to 
the cell lysate. The debris was removed by centrifugation. The collected supernatant was heated 
for 3 min after the temperature reached 53°C, and immediately transferred to the ice box. After 
centrifugation, 45% (w/v) ammonium sulfate was added to the supernatant and centrifuged to 
obtain pellets. The pellets were resuspended in buffer A (10 mM Tris-HCl, pH 7.4 containing 125 
mM KCl, 0.2 mM benzoate, 40 µM FAD and 4.5 µg. mL-1 PMSF), and dialyzed overnight against 
the same buffer. After centrifugation, the supernatant was applied to the DEAE Sepharose Fast 
Flow column (Sigma-Aldrich, USA) equilibrated with buffer A. The eluated fractions containing 
human DAO were detected based on the OD280/OD458 ratio using a spectrophotometer (DU600-
Beckman, USA), and precipitated with 70% (w/v) ammonium sulfate. After dialysis overnight 
against buffer B (50 mM sodium phosphate, pH 6.8 containing 0.2 mM benzoate and 40 µM 
FAD), the supernatant was loaded into the hydroxyapatite column (Nacalai Tesque, Japan), which 
was equilibrated with buffer B. Again, the eluated fractions containing human DAO were detected 
and precipitated with 70% (w/v) ammonium sulfate. Finally, the purified human DAO in holo 
form was obtained. The purity of DAO was confirmed by SDS-PAGE. The concentration of DAO 
was estimated with a BCA Protein Assay Kit (Pierce, Rockford, IL, USA) using BSA as a 
standard protein. 
The human DAO activity was determined based on the rate of oxygen consumption using an 
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carried out at 25°C in 100 mM sodium phosphate (pH 8.0), containing 20 µM FAD and 20 mM 
D-Ala. The enzymatic reaction was started by adding 0.1 µM human DAO. The concentration of 
holo DAO was determined based on the extinction coefficient at 458 nm (12.3 mM-1 cm-1). One 
unit of DAO activity was defined as the amount of enzyme that consumes 1 micromole of oxygen 
per min.
Preparation of apo DAO
In order to prepare apo DAO, holo DAO was dialyzed against 50 mM sodium pyrophosphate 
buffer (pH 8.3) containing 1 M KBr (31), 1 mM EDTA, and 1% (w/v) activated charcoal at 4°C 
until the yellow color of the holoenzyme solution disappeared. To completely remove KBr, the 
colorless solution containing apo DAO was dialyzed against the same buffer without KBr for one 
to two days. The concentration of apo DAO was determined based on the extinction coefficient 
at 280 nm (73 mM-1 cm-1) (32). 
Determination of kinetic parameters for holo and reconstituted DAOs
The procedures to determine the apparent kinetic parameters of holo and reconstituted DAOs 
were modified from the method used to characterize recombinant human DAO (20, 28). The 
composition of the pre-reaction mixture was 0.3 mM EDTA and 100 mM sodium phosphate (pH 
8.0). For the assays of reconstituted DAO, 0.1 µM apo DAO and 2 µM FAD were added to the 
pre-reaction mixture and incubated for 3 min. Subsequently, various concentrations (up to 10 
mM) of D-amino acid were added to start the reaction. The dissociation constant (Kd) of FAD 
from DAO was investigated by adding various concentrations of FAD. To determine the kinetic 
parameters of holo DAO, 50 mM sodium pyrophosphate (pH 8.3) was also used instead of sodium 
phosphate. FAD (20 µM) and various concentrations of D-amino acid were added to the pre-
reaction mixture and incubated in the presence (0.1-10 µM) or absence of benzoate before 0.1 
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calculated from conventional Michaelis-Menten equation (27, 33). The turnover number (kcat) is 
expressed as micromoles of oxygen consumed per min per micromole of DAO.    
X-ray crystallography and structure determination 
P219L DAO in the holo form mixed with 40 µM FAD and 0.2 mM benzoate was concentrated up 
to 12 mg. mL-1 using Centriprep (30 kDa cutoff, Merck Millipore, Germany). The screening of 
crystallization conditions was conducted by the hanging-drop vapor diffusion method. X-ray 
diffraction data were collected on beamline BL5A at Photon Factory. Scaling, molecular 
replacement and model building were performed with iMosfilm (34), XDS (35), MolRep (36) and 
Coot (37). Crystallographic refinement was carried out as previously described using Phenix (38, 
39). The Ramachandran plot of the final structure was validated by RAMPAGE (40). RMSD 
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Results
Preparation of wild-type and P219L DAOs
The amino acid sequence alignment showed that human DAO possesses Pro219, which is 
conserved in most mammalian DAOs (Fig. S2, A). However, porcine DAO possesses Leu at the 
corresponding position, which is located at the tip of the active site lid (Fig. S2, B). The 
conformation of the active site lid in human DAO was also different from porcine DAO (Fig. S2, 
B). To analyze the impact of the 219th residue on the activity and structure of human DAO, we 
produced wild-type and P219L mutant of human DAO. Both wild-type and P219L were expressed 
in E. coli cells under the same conditions. The cell walls were broken by lysozyme. The partial 
purification procedures were carried out by heat treatment at 53°C, in which the majority of holo 
human DAO molecules in complex with benzoate should be stable (42), followed by 45% (w/v) 
ammonium sulfate precipitation. The estimated yields of wild-type and P219L were 4 and 1.8 mg 
purified proteins per 1 L of culture after the final column chromatography with hydroxyapatite, 
respectively (Table S1). Moreover, the specific activities of purified wild-type and P219L were 
10.4 and 9.3 U/mg protein with 52-fold and 46.5-fold degrees of purity in comparison to the cell 
lysate, respectively. The purities of wild-type and P219L were confirmed by SDS-PAGE stained 
with Coomassie blue, as shown in Fig. S3, A and B, respectively. 
Determination of the kinetic parameters of wild-type and P219L under low and high FAD 
concentrations
To assess the functional characteristics of purified DAO, we used an oxygen electrode to measure 
the rate of oxygen consumption in the assay solution. According to our previous findings, human 
DAO preferably catalyzes uncharged D-amino acids (i.e., D-Ser, D-Ala, and D-Pro) (43). In the 
present work, we found that the kcat, Km, and kcat/Km values of wild-type for all tested substrates 
(D-Ser, D-Ala, and D-Pro) were consistent with our previous study. Since human DAO was 
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in the assay solution), was applied to reconstitute an active holo DAO and to examine its kinetic 
characteristics (Fig. 1). The kinetic parameters of wild-type were compared to those of P219L. 
The kcat values of holo DAOs of both wild-type and P219L in which DAOs were saturated with 
FAD were similar under high concentrations of FAD (Fig. 1A). In contrast, the Km values of wild-
type were approximately 2-fold greater than those of P219L for three different substrates (Fig. 
1B), which suggests that the substrate-binding affinity of wild-type is lower than that of P219L. 
The kcat/Km values of wild-type were approximately 2-fold lower than those of P219L (Fig. 1C). 
Among tested substrates, it is suggested that D-Ala has the strongest binding affinity for both 
wild-type and P219L based on the smallest Km values, followed by D-Pro. It is suggested that D-
Ser has the weakest binding affinity for human DAO. D-Pro showed the highest catalytic 
efficiency (kcat/Km) in the cases of both wild-type and P219L, followed by D-Ala and D-Ser.
The physiological FAD concentrations in various organs in mice are in the range of 2-15 µM 
(44). Thus, the effect of a low FAD concentration (final conc. ~2 µM FAD in the assay 
solution) was examined to mimic the physiological condition in the kinetic analysis using 
reconstituted human DAO from apo DAO and FAD. The kcat values of both wild-type and 
P219L were similar (Fig. 2A). However, P219L showed approximately 2-fold lower Km values 
and higher kcat/Km values in comparison to wild-type for all substrates, as observed in Fig. 2B 
and 2C, respectively. These values are in good agreement with our previous values of wild-type 
human DAO in the condition with a low concentration of FAD (45). The Kd for FAD was 
estimated from a Lineweaver-Burk plot in which the initial velocities of the reactions were 
plotted against the concentrations of FAD. We found that the Kd value of P219L was slightly 
but significantly different from that of wild-type (P219L; 0.146 ± 0.009 µM, wild-type; 0.173 ± 
0.003 µM, p < 0.01). The Kd value of wild-type was consistent with our previous study (28). 
The kinetic parameters of reconstituted human DAO in the condition with a low concentration 
of FAD (Fig. 2) were compared to the parameters of holo-human DAO in the condition with a 
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for all the substrates were greater than those of holo-human DAO (Fig. 1B). However, the kcat 
and kcat/Km values of FAD-reconstituted human DAO, as shown in Fig. 2A and 2C, were lower 
than those of holo-human DAO (Fig. 1A and 1C). Our results with low and high concentrations 
of FAD indicated that the replacement of Pro at position 219 located in the active site lid of 
human DAO with Leu alters the substrate-binding affinity (Km) and catalytic efficiency (kcat/Km) 
of the enzyme. In addition, both wild-type and P219L preferred to catalyze hydrophobic 
substrates (D-Ala and D-Pro) in comparison to the hydrophilic substrate (D-Ser), because the 
hydrophobic substrates showed higher kcat/Km and lower Km values.
Alteration of the affinity for benzoate with P219L substitution
Subsequently, we determined the inhibition constant (Ki) of the competitive inhibitor benzoate 
for human DAO. The initial velocities of enzymatic reaction were measured under various 
benzoate concentrations and fitted to a Lineweaver-Burk plot. We found that the Ki values of 
benzoate for wild-type were in the range of 1.2-2.0 µM with three different substrates, including 
D-Pro, D-Ala and D-Ser, while the values for P219L were in the range of 0.7-0.9 µM. These Ki 
values for P219L were approximately 2-fold lower than those for wild-type (Fig. 3). In other 
words, P219L showed tighter binding to the inhibitor benzoate than wild-type. The observed Ki 
values for P219L with the substrates D-Pro and D-Ser were significantly lower than those for 
wild-type. These results indicated that the P219L substitution altered the inhibition constant (Ki) 
of benzoate.
Structure determination of P219L in complex with FAD and benzoate
In order to provide a structural basis for the difference in the kinetic parameters between wild-
type and P219L, we determined the crystal structure of the ternary complex of P219L, FAD and 
benzoate at 2.25 Å resolution. The statistics for data collection and refinement are summarized 
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wild-type complex (PDB ID: 2DU8) (20) with a backbone RMSD value of ~0.4 Å. We found 
that the B-factor of benzoate of the P219L complex (39.30 Å2) (Table ΙΙ) was lower than that of 
the wild-type complex (60.29 Å2) (20) whereas the B-factors of the other regions showed 
comparable values between these ternary complexes. These results indicated that the mobility of 
benzoate in the wild-type complex may be different from that in the P219L complex. The 
conformation of the hydrophobic stretch (residues 47-51, VAAGL) in P219L was virtually 
identical to that in wild-type with a backbone RMSD value of ~0.2 Å. The distance between the 
isoalloxazine ring N5 atom and the Ala49 backbone N atom in P219L was similar to that in 
wild-type (P219L; 3.91 ± 0.08 Å, wild-type; 3.78 ± 0.08 Å). These results suggested that the 
P219L substitution did not affect the conformation of the hydrophobic stretch in human DAO.
Structure of the active site and the active site lid 
A negative charge at benzoate was neutralized by Arg283 of P219L, which also formed H-
bonds with benzoate together with Tyr228 (Fig. 4A). The aromatic ring of benzoate was 
sandwiched between the isoalloxazine ring of FAD and the side chain ring of Tyr224. These 
characteristics are in excellent agreement with the wild-type structure (20). The distances 
between the carboxylate group of benzoate and H-bond donors in Tyr228 and Arg283 of P219L 
were shorter than those in the wild-type complex, suggesting stronger binding in the P219L 
complex ((1) - (3) in Fig. 4A). The benzoate-FAD distance in the wild-type complex was 
slightly different from that in the P219L complex ((4), (5) in Fig. 4A). Thus, the relative 
position of benzoate with respect to FAD differed between the wild-type and P219L complexes. 
These results are consistent with the results of the kinetic analysis of human DAO inhibition, as 
shown in Fig. 3, in which the Ki value of benzoate for P219L was approximately 2-fold lower 
than that for wild-type, suggesting stronger binding of P219L with benzoate. 
The conformation of the active site lid of P219L was slightly different from wild-type (Fig. 
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forming atoms in the active site lid, and found that the H-bond distances of Asp218 (C=O) - 
Arg221 (NH) and Asp218 (C=O) - Gly222 (NH) of P219L were altered in comparison to wild-
type (Fig. 4B). However, the H-bond distances of Gly222 (C=O) - Asn225 (NH) and Pro227 
(C=O) - Thr216 (NH) of P219L were similar to wild-type. In addition, the B-factor of amino 
acid residues in the active site lid in P219L (49.65 Å2) was lower than that in wild-type (57.95 
Å2) (Table S2). In particular, the B-factor of Tyr224 in P219L was 41.76 Å2, whereas that in 
wild-type was 58.72 Å2. These results suggested that the P219L substitution affects the 
conformation and flexibility of the active site lid for substrate entry and product release. 
The structural change of Tyr224 and benzoate in the P219L complex 
The aromatic ring of Tyr224 plays an important role as the gate to sequester the active site of 
human DAO from solvent (46). In comparison to the wild-type complex, the relative location of 
the aromatic ring of benzoate with respect to that of Tyr224 in the P219L complex was shifted 
(Fig. 5). This movement may influence the extent of the π-π interaction between these aromatic 
rings. These results indicated that the P219L substitution could alter the binding affinity 
between Tyr224 and ligands, including substrates and inhibitors.
Acetic acid in the ternary complex of P219L 
We found a pronounced blob at one of the entrance/exit pathways of the cavity that 
accommodates FAD in the electron density map of individual P219L molecules within the 
asymmetric unit (Fig. 6A). The blob was close to the pocket that accommodates the adenine 
ring of FAD, the adenine ring pocket. The shapes of the blobs were identical to that of the acetic 
acid molecule, which was one of the compounds used to prepare the crystal (Fig. S4). Thus, the 
blobs in molecule B (Fig. S4) and D within the asymmetric unit were identified as acetic acid. A 
water molecule located closely to the acetic acid molecule bridged the acetic acid, adenine ring 
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acid residues surrounding the acetic acid molecule were negative (i.e., Asp37, Glu165, and 
Glu249), positive (i.e., Arg38, and Lys163), aromatic (i.e., Trp185), and other residues (i.e., 
Thr43, and Ala188) (Fig. 6B). 
Accession code 
The structure factors of the P219L and its atomic coordinates have been deposited in the Protein 
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Discussion
In the present study, we investigated the impact of the replacement of Pro219 at the active site 
lid with Leu on the structure and function of human DAO, because porcine DAO has Leu at the 
corresponding position. We found differences in the kinetic parameters (i.e., Km, kcat/Km and Ki 
values) between P219L and wild-type DAOs in conditions with high and low concentrations of 
FAD. In addition, the structures of the active site and the lid of the P219L complex were 
different from those of the wild-type complex. We also found an acetic acid molecule that was 
located close to the adenine ring of FAD in the P219L complex. 
The Km values of P219L were lower than those of wild-type (Fig. 1B and 2B). In other 
words, P219L has stronger substrate-binding affinity than wild-type. Among tested D-amino 
acids, D-Ala showed the smallest Km value for both P219L and wild-type, which suggests the 
strongest binding affinity of D-Ala to DAO. The side chain of D-Ala has stronger 
hydrophobicity than the other D-amino acids used in the present study (i.e., D-Pro and D-Ser) 
(47). A substrate side chain in the substrate-binding pocket of DAO extends toward the 
secondary pocket, which is formed by an array of several hydrophobic residues (39, 43, 48). 
Thus, the hydrophobic side chains of substrates are stabilized in the secondary pocket through 
hydrophobic interactions. The kcat values were similar between P219L and wild-type in both the 
high (final conc. ~20 µM, Fig. 1) and low (final conc. ~2 µM, Fig. 2) FAD concentrations (Fig. 
1A and 2A). The rate-limiting step of human DAO catalysis has been defined as that of product 
release (21), which suggests that the P219L substitution did not impact the rate of oxygen 
consumption of the enzyme. These findings suggested that the conformation of the active site 
or/and the active site lid in P219L was not associated with the product dissociation rate of the 
enzyme. 
We investigated the impact of a change in the FAD concentration on the characteristics of 
human DAO. The condition with a low concentration of FAD mimicked the physiological FAD 
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of FAD. Km values of FAD-reconstituted human DAO with a low concentration of FAD were 
greater than those of holo-human DAO in the condition with a high concentration of FAD, 
while kcat and kcat/Km values were lower (Fig. 2). Interestingly, the profiling patterns of the 
individual kinetic parameters depending on substrate species were quite similar between the 
conditions with low and high concentrations of FAD, although the magnitude of these 
parameters differed between the conditions (Fig. 1, 2). Our previous study reported that human 
DAO weakly interacts with FAD (21). The conformation of the hydrophobic stretch (residues 
47-51, VAAGL) in human DAO was suggested to play a key role in the binding affinity for 
FAD (20). In the present study, the conformation of the hydrophobic stretch in P219L was 
virtually identical to that in wild-type. The Kd for binding of FAD to P219L was slightly 
different from that to wild-type. In addition, both holo- and apo-human DAOs, which are in 
equilibrium under physiological conditions, are stable as a homodimer (21). Thus, we 
hypothesize that the kinetic analysis under the low concentration of FAD reflects the dynamic 
regulation of DAO activity in the equilibrium between holo- and apo- human DAO under the 
physiological condition. 
It has been reported that the hydroxy group of Tyr228 and guanidino group of Arg283 play 
important roles in the binding between DAO and ligands (20, 27, 49, 50). The crystal structure 
of the ternary complex of P219L, FAD and benzoate revealed that the conformation of the 
active site lid was altered in comparison to wild-type (Fig. 4B). The distances between the H-
bond-forming atoms of Arg283, Tyr228 and benzoate (Fig. 4A), as well as the relative position 
between the aromatic rings of Tyr224 and benzoate (Fig. 5), were also altered in the P219L 
complex. We hypothesize that the replacement of Pro219 with Leu leads to the loop region 
more flexible because Pro gives the rigidity in the conformation of the mainchain. The 
flexibility impacts the positional shift of Tyr224. However, it may be difficult to accurately 
evaluate the conformational changes of the active site lid of P219L compared to wild-type due 
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In addition, the B-factor for benzoate in the P219L complex was different from the wild-type 
complex (Table ΙΙ and Fig. 5). These changes in the P219L complex caused a decrease in the 
inhibition constant (Ki) of benzoate, that is, an increase in the affinity for benzoate, compared 
with wild-type (Fig. 3) in part through the change in the extent of the π-π interaction between 
Tyr224 and benzoate aromatic rings. The π-π interaction between two benzene aromatic rings is 
most stable when the aromatic rings are in the parallel-displaced conformer, as observed in the 
Tyr224 and benzoate of the DAO complexes (51). In the reductive half-reaction of DAO, 
Tyr224 could stabilize the second charge-transfer intermediate by interacting with the positive 
charge of imino acid (23). Tyr224 residue is involved not only in the interaction with benzoate 
(24) but also plays an important role in the determination of substrate specificity (22, 26). 
Therefore, the relative position between Tyr224 and a substrate/inhibitor is presumed to be an 
indispensable factor in determining the binding affinity and specificity of human DAO to 
substrates/inhibitors. 
Hallberg et al. reported that acetate molecule was bound to the active site of the flavoenzyme 
pyranose 2-oxidase (52). They also confirmed that acetate, originated from the buffer used for 
crystallization, was a competitive inhibitor of this enzyme. However, the acetate molecule 
binding to any of DAO structure has not been reported so far. In the P219L complex, an acetic 
acid molecule was located close to an adenine ring of FAD (Fig. 6). The presence of the acetic 
acid molecule might impact the binding affinity of FAD, because the acetic acid molecule 
appears to contribute to stabilizing the conformation of the adenine ring pocket by polar 
interactions with charged residues around the pocket, as well as H-bonds through a bridging 
water molecule. The adenine ring was surrounded by the acetic acid molecule and an adenine-
binding motif composed of Ile6, Lys163, Val164 and Glu165 (53). The aliphatic-aromatic 
interactions play an important role in packing of adenine ring in the adenine binding pocket of a 
protein (54). In addition to the adenine-surrounding residues, including Ile6 and Val164, the 
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aliphatic-aromatic interaction to stabilize the structure of the adenine-binding pocket. The 
functional relevance of the acetic acid binding to the enzyme remains to be investigated.
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Figure legends
Fig. 1 Apparent kinetic parameters of holo-human DAO with a high concentration of 
FAD. The kinetic parameters of holo wild-type and P219L DAOs were determined with a 
saturated FAD concentration (final conc. ~20 µM) and are displayed as the (A) kcat, (B) Km, and 
(C) kcat/Km values. Data are presented as the mean ± SD (n = 3 for wild-type and n = 4 for 
P219L). *p < 0.05, ***p < 0.001 (Student’s t-test) in comparison to control (wild-type human 
DAO).
 
Fig. 2 Apparent kinetic parameters of FAD-reconstituted human DAO with a low 
concentration of FAD. The kinetic parameters of reconstituted wild-type and P219L DAOs 
were determined with a low concentration of FAD (final conc. ~2 µM) and are displayed as the 
(A) kcat, (B) Km, and (C) kcat/Km values. Data are presented as the mean ± SD (n = 3 for wild-type 
and n = 4 for P219L). *p < 0.05, **p < 0.01, ***p < 0.001 (student’s t-test), compared with 
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Fig. 3 The inhibition constant (Ki) of benzoate for wild-type and P219L DAOs. The Ki 
values are presented as the mean ± SD (n =3 for wild-type and n = 4 for P219L). *p < 0.05, 
***p < 0.001 (Student’s t-test) in comparison to control (wild-type human DAO).
Fig. 4 Distances between atoms around the active site and the lid of P219L and wild-type 
DAOs. (A) Atomic distances in the active site of human DAO complexed with benzoate and 
FAD. The distances were calculated by Swiss-PdbViewer (41) and are presented as the mean ± 
SD of 4 molecules within the asymmetric unit. The distances between atoms forming H-bonds 
((1) - (3)) are displayed as dashed green lines, whereas those between the atoms of benzoate and 
FAD ((4), (5)) are displayed as black arrows. The orange arrows indicate possible 𝜋-𝜋 
interactions. (B) Atomic distances between H-bond-forming atoms in the active site lid of 
human DAO. The superimposed structures of the active site lids (residue 216-228) of P219L 
and wild-type are shown as green and orange lines, respectively. The dashed green lines indicate 
the atomic distances in the active site lid between (1) Asp218 (C=O) - Arg221 (NH), (2) 
Asp218 (C=O) - Gly222 (NH), (3) Gly222 (C=O) - Asn225 (NH), and (4) Pro227 (C=O) - 
Thr216 (NH). 
Fig. 5 The structural change of Tyr224 and benzoate in the P219L complex. (A) Top views 
of Tyr224 and benzoate in the ternary complexes. The left panel shows the superimposed 
structures of the wild-type (PDB ID: 2DU8) and P219L complexes, whereas the middle and 
right panels separately show the structures of the wild-type and P219L complexes, respectively. 
The line model of Tyr224 of P219L is colored in green, whereas the other line models are 
colored in CPK. The yellow arrows indicate the directions of the movement of Tyr224 and 
benzoate in the P219L complex with respect to those in the wild-type complex. The dotted black 
lines between the aromatic rings of Tyr224 and benzoate indicate mean atomic distances of 4 
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Fig. 6 Acetic acid in the ternary complex of P219L. (A) Cross section of a monomer of 
P219L with surface charge distribution. In the complex structure, FAD and benzoate were 
located within the internal cavity, whereas the acetic acid molecule was located at one of the 
entrance/exit pathways of the cavity. (B) The sphere model of the acetic acid molecule 
surrounded by several amino acid residues around the adenine ring pocket. Atoms other than 
carbons are colored in CPK, whereas the carbons of P219L residues, FAD and acetic acid are 
colored in gray, pale cyan, and pale green, respectively. The H-bond between acetic acid and 
water is represented as a yellow line.  
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Table Ι. Data collection statistics. 
Data collection
X-ray source Photon Factory BL5A
Wavelength (Å) 1.000　
Space group P21212
Unit cell a, b, c (Å) 149.49, 182.78, 51.04
Resolution (Å) 48.30 – 2.25 (2.30 – 2.25)
Unique reflections 67,535 (4,496)
Rmeas 0.066 (1.002)
I/σI 21.3 (2.2) 
Completeness (%) 99.9 (100.0)
Redundancy 6.6 (6.4)
half-data set correlation (CC (1/2)) 1.00 (0.81)
a Highest resolution shell is shown in parentheses.
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Table ΙΙ. Refinement statistics. 
Refinement P219L




   Bond lengths (Å) 0.009
   Bond angles (°) 1.163
No. atoms
   Protein 10,833
   FAD 212
   Benzoate 36
   Acetic acid 8
   Water 390
Average B-factors (Å2)
   Overall 46.77
   Protein 47.01
   FAD 37.95
   Benzoate 39.30
   Acetic acid 57.48
   Water 45.44
Ramachandran plot a
   Favored region 95.8%
   Allowed region 4.2%
   Outlier region 0.0%
PDB code 6KBP
a Analyzed by RAMPAGE (40).
b The highest resolution shell is shown in parentheses. 
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